Viking Therapeutics, Inc. rebounded 50% after a sharp drop, returning to pre-selloff levels despite no major internal catalysts. VKTX's recovery is likely driven by broader developments in the GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results